
End-Stage Renal Disease - Pipeline Insight, 2024
Description
End-Stage Renal Disease - Pipeline Insight, 2024
DelveInsight’s, “End-Stage Renal Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in End-Stage Renal Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
End-Stage Renal Disease: Overview
End-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease — the gradual loss of kidney function — reaches an advanced state. In end-stage renal disease, the kidneys are no longer able to work as they should to meet the body's needs. End stage renal disease (ESRD) is the last stage (stage five) of chronic kidney disease (CKD). This means kidneys are only functioning at 10 to 15 percent of their normal capacity. When chronic kidney disease develops into ESRD, dialysis or a kidney transplant is necessary to stay alive. ESRD is caused most commonly due to diabetes and hypertension (high blood pressure). The treatments for ESRD are dialysis or a kidney transplant. In some cases, lifestyle changes and medications may help.
""End-Stage Renal Disease- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the End-Stage Renal Disease pipeline landscape is provided which includes the disease overview and End-Stage Renal Disease treatment guidelines. The assessment part of the report embraces, in depth End-Stage Renal Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, End-Stage Renal Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence End-Stage Renal Disease R&D. The therapies under development are focused on novel approaches to treat/improve End-Stage Renal Disease.
This segment of the End-Stage Renal Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
End-Stage Renal Disease Emerging Drugs
- AB002: Aronora, Inc.
- ISIS 416858: Ionis Pharmaceuticals
Further product details are provided in the report……..
End-Stage Renal Disease: Therapeutic Assessment
This segment of the report provides insights about the different End-Stage Renal Disease drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in End-Stage Renal Disease
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Mid-stage products (Phase II and Phase I/II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
End-Stage Renal Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Parenteral
- Intramuscular
- Molecule Type
- Small molecules
- Peptides
- Polymer
- Gene Therapy
- Monoclonal antibodies
- Product Type
End-Stage Renal Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses End-Stage Renal Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging End-Stage Renal Disease drugs.
End-Stage Renal Disease Report Insights
- End-Stage Renal Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing End-Stage Renal Disease drugs?
- How many End-Stage Renal Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of End-Stage Renal Disease?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the End-Stage Renal Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for End-Stage Renal Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
- Aronora Inc.
- Ionis Pharmaceuticals
- Janssen Research & Development, LLC
- Ardelyx
- AZD1722
- AB002
- ISIS 416858
- Rivaroxaban
Table of Contents
40 Pages
- Introduction
- Executive Summary
- End-Stage Renal Disease: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- End-Stage Renal Disease – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- End-Stage Renal Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- End-Stage Renal Disease Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- AB002: Aronora Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- End-Stage Renal Disease Key Companies
- End-Stage Renal Disease Key Products
- End-Stage Renal Disease- Unmet Needs
- End-Stage Renal Disease- Market Drivers and Barriers
- End-Stage Renal Disease- Future Perspectives and Conclusion
- End-Stage Renal Disease Analyst Views
- End-Stage Renal Disease Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.